Revenue: As of FY2026 Q2, the actual value is USD 32.01 M, beating the estimate of USD 31.46 M.

EPS: As of FY2026 Q2, the actual value is USD -0.53, beating the estimate of USD -0.594.

EBIT: As of FY2026 Q2, the actual value is USD -25.58 M.

Second Quarter 2026 Financial Highlights

Net Sales

Beta Bionics, Inc. reported net sales of $32.0 million for the second quarter of 2026, marking a 38% increase compared to $23.2 million in the second quarter of 2025. Durable Medical Equipment (DME) channel net sales were $20.4 million, an increase of 9% from $18.6 million in the second quarter of 2025. Pharmacy Benefit Plan (PBP) channel net sales surged by 153% to $11.6 million, up from $4.6 million in the second quarter of 2025.

Gross Margin

Gross margin for the quarter was 59.0%, an increase of 524 basis points from 53.8% in the second quarter of 2025.

Operational Metrics

Loss from operations was - $25.6 million, representing negative 80% of sales, compared to - $19.9 million or negative 86% of sales in the second quarter of 2025. Net loss was - $23.4 million, or negative 73% of sales, which was comparable to - $16.9 million or negative 73% of sales in the second quarter of 2025. Adjusted EBITDA was - $17.7 million, or negative 55% of sales, compared to - $14.5 million or negative 63% of sales in the second quarter of 2025.

New Patient Starts

New patient starts increased by at least 10% but less than 20% sequentially compared to the first quarter of 2026. Of these, 69% originated from multiple daily injections (MDI), and a high 30s percentage were reimbursed through the PBP channel.

Cash and Investments

As of June 30, 2026, Beta Bionics, Inc. held $225.2 million in cash, cash equivalents, short and long-term investments.

Six Months Ended June 30, 2026 Financial Highlights

Net Sales

For the six months ended June 30, 2026, total net sales were $59,639 thousand, compared to $40,877 thousand for the same period in 2025. DME channel net sales totaled $37,336 thousand, up from $32,471 thousand in 2025. PBP channel net sales reached $22,303 thousand, a significant increase from $8,406 thousand in 2025.

Gross Margin

Gross margin for the six-month period was 59.3%, an improvement from 52.5% in the prior year period.

Operational Metrics

Loss from operations for the six months was - $49,849 thousand, compared to - $38,514 thousand in 2025. Net loss was - $45,298 thousand, a slight improvement from - $45,525 thousand in 2025. Adjusted EBITDA was - $35,374 thousand, compared to - $30,061 thousand in 2025.

Cash Flow

The provided reference does not include a cash flow statement.

2026 Full Year Guidance

Beta Bionics, Inc. maintains its estimated total revenue forecast at $131 million to $136 million for the full year 2026. The company expects 37% to 39% of new patient starts to be reimbursed through the PBP channel, unchanged from previous guidance. The estimated gross margin for the full year has been updated to 58.5% to 59.5%, a slight adjustment from the previously stated 57.5% to 59.5%.